• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Enveric Biosciences

    < Previous 1 2 Next >
    Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at the Centurion One 5th Global Summit
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at the BIO CEO & Investor Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022
    From Enveric Biosciences
    Via Business Wire
    Tickers ENVB
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.